New Horizon Stages $263 Million HK IPO for Cancer Screening Tests

New Horizon Health staged a $263 million IPO last week on the Hong Kong Exchange to support its early cancer screening tests. The stock tripled in trading, giving the company a market cap of $4.3 billion. New Horizon markets two stool based tests in China : ColoClear, a multi-target, FIT-DNA test aimed at people at risk for colorectal cancer, and Pupu Tube, a self-administered FIT test intended to screen a larger population. The company also has two late-stage product candidates for gastric and cervical cancer screening. More details.... Stock Symbol: (HK: 6606) Share this with colleagues: // //